AEON Biopharma, Inc. (AEON)
After hours:
| Previous close | 1.6600 |
| Open | 1.6800 |
| Bid | 1.6100 x 2900 |
| Ask | 1.7900 x 1100 |
| Day's range | 1.6200 - 1.7400 |
| 52-week range | 1.3800 - 17.1700 |
| Volume | |
| Avg. volume | 92,859 |
| Market cap | 67.094M |
| Beta (5Y monthly) | 0.76 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.3400 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ZacksAEON Biopharma, Inc. (AEON) Loses -79.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
AEON Biopharma, Inc. (AEON) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
GlobeNewswireAEON Biopharma Provides Update on Development Pipeline
Includes two late-stage clinical programs and two early-stage clinical programsIRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today provided an update on the status of its late-stage clinical pipeline for ABP-450 that targets multiple indications. “In addition to our ear
- GlobeNewswire
AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine
– Trial did not meet primary endpoint –IRVINE, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today announced that the preliminary top-line results from its planned interim analysis of the Phase 2 trial with ABP-450 in the preventive treatment for chronic migraine did not meet t
